Literature DB >> 18326532

Imatinib for the treatment of refractory, diffuse systemic sclerosis.

P P Sfikakis, V G Gorgoulis, C G Katsiari, K Evangelou, C Kostopoulos, C M Black.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18326532     DOI： 10.1093/rheumatology/ken104

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  26 in total

1.  Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease.

Authors:  Athanasios Koutroumpas; Athanasios Ziogas; Ioannis Alexiou; Georgia Barouta; Lazaros I Sakkas
Journal:  Clin Rheumatol       Date:  2010-06-10       Impact factor: 2.980

Review 2.  The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis.

Authors:  Yoshihide Asano; Andreea M Bujor; Maria Trojanowska
Journal:  J Dermatol Sci       Date:  2010-07-03       Impact factor: 4.563

Review 3.  Targeted therapy for systemic sclerosis: how close are we?

Authors:  Manuel Ramos-Casals; Vicent Fonollosa-Pla; Pilar Brito-Zerón; Antoni Sisó-Almirall
Journal:  Nat Rev Rheumatol       Date:  2010-04-13       Impact factor: 20.543

Review 4.  Tyrosine kinases in inflammatory dermatologic disease.

Authors:  Ricardo T Paniagua; David F Fiorentino; Lorinda Chung; William H Robinson
Journal:  J Am Acad Dermatol       Date:  2010-06-26       Impact factor: 11.527

Review 5.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 6.  Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials.

Authors:  Naoki Iwamoto; Jörg H W Distler; Oliver Distler
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

Review 7.  Vasculopathy in scleroderma.

Authors:  Yoshihide Asano; Shinichi Sato
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

8.  Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis.

Authors:  Anagha A Divekar; Dinesh Khanna; Fereidoun Abtin; Paul Maranian; Rajeev Saggar; Rajan Saggar; Daniel E Furst; Ram Raj Singh
Journal:  Clin Immunol       Date:  2011-09-05       Impact factor: 3.969

9.  Tyrosine kinase inhibitors in systemic sclerosis: the case for imatinib.

Authors:  Flavia V Castelino; Swati Bhattacharyya; John Varga
Journal:  Curr Rheumatol Rep       Date:  2009-07       Impact factor: 4.592

10.  Molecular framework for response to imatinib mesylate in systemic sclerosis.

Authors:  Lorinda Chung; David F Fiorentino; Maya J Benbarak; Adam S Adler; Melissa M Mariano; Ricardo T Paniagua; Ausra Milano; M Kari Connolly; Boris D Ratiner; Robert L Wiskocil; Michael L Whitfield; Howard Y Chang; William H Robinson
Journal:  Arthritis Rheum       Date:  2009-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.